Pharmacokinetics of Caspofungin in Critically Ill Patients on Continuous Renal Replacement Therapy
Pharmacokinetics of Caspofungin in Critically Ill Patients on Continuous Renal Replacement Therapy
复制标题
DOI：
10.1128/aac.00335-13
复制
发表时间：
2013-08-01
影响因子：
4.9
通讯作者：
Bellmann, Romuald
中科院分区：
文献类型：
--
作者：
Weiler, Stefan;Seger, Christoph;Bellmann, Romuald
对27例危重患者进行了卡泊芬净药代动力学研究，其中7例接受连续性静脉-静脉血液滤过(CVVH)，8例接受连续性静脉-静脉血液透析(CVVHD)，13例不需要连续性肾脏替代治疗(CRRT)。卡泊芬净在CRRT中的暴露与对照组非常相似，与健康志愿者相当。CRRT的卡泊芬净清除率很低。因此，卡泊芬净的标准剂量对于接受CVVH或CVVHD的危重患者来说可能是足够的。
Caspofungin pharmacokinetics was assessed in 27 critically ill patients, including 7 on continuous venovenous hemofiltration (CVVH), 8 on continuous venovenous hemodialysis (CVVHD), and 13 not requiring continuous renal replacement therapy (CRRT). Caspofungin exposure during CRRT was very similar to that of the control group and comparable to that in healthy volunteers. Caspofungin clearance by CRRT was very low. Therefore, the standard dosage of caspofungin is probably adequate for critically ill patients undergoing CVVH or CVVHD.